- Home
- YQ vs BRTX Comparison
YQ vs BRTX Comparison
Compare YQ & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- BRTX
- Stock Information
- Founded
- YQ 2012
- BRTX 1997
- Country
- YQ China
- BRTX United States
- Employees
- YQ N/A
- BRTX N/A
- Industry
- YQ Other Consumer Services
- BRTX Managed Health Care
- Sector
- YQ Real Estate
- BRTX Health Care
- Exchange
- YQ Nasdaq
- BRTX Nasdaq
- Market Cap
- YQ 13.1M
- BRTX 11.3M
- IPO Year
- YQ 2020
- BRTX N/A
- Fundamental
- Price
- YQ $1.63
- BRTX $1.41
- Analyst Decision
- YQ
- BRTX Strong Buy
- Analyst Count
- YQ 0
- BRTX 1
- Target Price
- YQ N/A
- BRTX $18.00
- AVG Volume (30 Days)
- YQ 42.7K
- BRTX 100.5K
- Earning Date
- YQ 12-11-2024
- BRTX 11-12-2024
- Dividend Yield
- YQ N/A
- BRTX N/A
- EPS Growth
- YQ N/A
- BRTX N/A
- EPS
- YQ N/A
- BRTX N/A
- Revenue
- YQ $28,507,378.00
- BRTX $377,000.00
- Revenue This Year
- YQ N/A
- BRTX $482.76
- Revenue Next Year
- YQ N/A
- BRTX $212.24
- P/E Ratio
- YQ N/A
- BRTX N/A
- Revenue Growth
- YQ 22.55
- BRTX 189.55
- 52 Week Low
- YQ $1.47
- BRTX $1.03
- 52 Week High
- YQ $3.55
- BRTX $3.67
- Technical
- Relative Strength Index (RSI)
- YQ 31.56
- BRTX 41.13
- Support Level
- YQ $1.50
- BRTX $1.40
- Resistance Level
- YQ $1.92
- BRTX $1.60
- Average True Range (ATR)
- YQ 0.20
- BRTX 0.10
- MACD
- YQ -0.01
- BRTX 0.00
- Stochastic Oscillator
- YQ 16.13
- BRTX 42.86
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers to assist students, teachers, schoolmasters, and educational authorities across China to achieve data-driven teaching, learning, and assessment. Geographically group operates in China.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.